Academia Sinica

Taiwan Semiconductor Manufacturing Comp. Ltd.

Cho Pharma Inc.

National Taiwan University

Asustek Computer Inc.

Rock Biomedical, Inc.

Wu; Chung-yi

Tsai, Tsung-i

Wong, Chi-heuy

Chung-Yi Wu

Chi-Huey Wong

Cheng Hung Lee

Hsu-Shun Chen

Hong-Chen Cheng

Chen-Lin Yang

Han-Chung Wu

Alice L Yu

Chung-Ji Lu

Tsui-Ling Hsu

John Yu

Sachin S Shivatare

Yu-Hao Hsu

Nan-Horng Lin

Chih-Chieh Chiu

Che Ma

Ting-Jen Rachel Cheng

Shih-Hsiung Wu

Ming-Chien Tsai

Lin-Ya Huang

Hung-Jen Liao

Chien-Yu Chen

Jim-Min Fang

Cheng-Hung Lee

Chia-Hung Wang

Wei-Long Lee

An-Suei Yang

Cheng-Chi Wang

Chao-Yang Huang

Uppu Sharath Chandra

Yih-Shyun Edmond Cheng

Yi-Wei Lou

Chih-Wei Lin

Shih-Chi Yeh

Li-Tzu Chen

Ting Cheng

Chi-Hui Liang

Susan Y Tseng

Jin-Town Wang

Hsien-Yeh Hsu

Jia-Tsrong Jan

Chung-Hsien Hua

Szu-Wen Wang

Shih-Fen Liao

Ming-Hung Tsai

Kuo-Ching Chu

Chen-Yo Fan

Tsung-I Tsai

Jeng Shin Lee

Ju-Mei Li

Sarah K C Cheung

Po-Kai Chuang

Mei-Chieh Ku

Tzu-Yu Kung

I-Ming Lee

Tai-Yin Lin

Feng-Ling Yang

Jia-Wei Chou

Hsin-Yu Lee

Hong-Yang Chuang

Chien-Tai Ren

Shiou-Ting Li

Lee-Cheng Hung

Hui-Ming Yu

Alice Yu

Sarah KC Cheung

Che-Hsiung Hsu

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

Methods and compositions for dendritic cell targeting nano-delivery

The present disclosure relates to a composition for inducing immune response comprising a glycoengineered antibody or antigen-binding fragment thereof that is specific for an antigen portion having a receptor binding domain (RBD) of a surface protein of a virus. The present disclosure also relates to an immune combination and a method for treating an infection by a virus.

Immune composition comprising antigen and glycoengineered antibody thereof

Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.

Recombinant virus, composition comprising the same, and uses thereof

The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Anti-CD20 glycoantibodies and uses thereof

Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.

Methods for modifying human antibodies by glycan engineering

The present disclosure relates to a novel class of anti-TNF&#x3b1; monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNF&#x3b1; IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNF&#x3b1; monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Anti-TNF-alpha glycoantibodies and uses thereof

Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.

Disclosed herein is a glycoconjugate vaccine conferring protection against a Gram negative pathogen infection, a method of manufacturing the glycoconjugate vaccine, and use of the glycoconjugate vaccine for treating bacterial infection. The glycoconjugate vaccine of the present disclosure has the structure of formula (I), wherein, L is a maleimide-type linker, which is connected to the carrier protein via a maleimide bond formed therebetween; and n and m are independently an integral or a non-integral number between 2 and 20.

Glycoconjugate vaccines, preparation method and uses thereof

The disclosure provides various immunogens comprising a repeat unit of saccharide ofCPS, which has a formula selected from the group consisting of Formulae (I) to (VI) as described herein. Also provided are vaccines including one or more immunogens selected from Formula (I) to (VI) and methods of eliciting an immune response against aand preventing infection ofby using an immunogen of the invention.

capsule polysaccharide vaccines

The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Anti-HER2 glycoantibodies and uses thereof

The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

Cancer markers and methods of use thereof

An electronic device is provided. The electronic device comprises: a storage for storing interaction setting information and behavior setting information; an interaction interface; and a processor electrically connected to the storage and the interaction interface. When the processor receives a behavior-driving command from the interaction interface, the processor is configured to select the behavior setting information and the interaction setting information according to the behavior-driving command. The processor is configured to perform a behavior according to the behavior setting information. The processor is further configured to perform an interaction operation based on the behavior according to the behavior setting information and the interaction setting information when the behavior is had. A control method and a non-transitory computer readable storage medium are also provided.

Control method, electronic device and non-transitory computer readable storage medium

A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

Methods for glycoprotein remodeling using endoglycosidase mutants

The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.

Glycan conjugates and methods of use thereof

Growing community of inventors

Taipei, Taiwan

Chung-Yi Wu